Rossari Biotech Ltd · NSE:ROSSARI
Rossari Biotech — Q4 FY26 Earnings Presentation
33 slides from Rossari Biotech's earnings presentation, Apr 28, 2026
Slide 1: Cover letter to stock exchanges: Q4 & FY26 Earnings Presentation
April 28, 2026 DCS-CRD Listing Compliance BSE Limited National Stock Exchange of India Limited First Floor, New Trade Wing Exchange Plaza, 5th Floor Rotunda Building, Phiroze Jeejeebhoy Towers Plot No. C/1, ‘G’ Block, Bandra- Kurla Complex Dalal Street, Fort Mumbai 400001 Bandra East Mumbai 400051 F
Slide 2: Q4 & FY26 Results Presentation
ROSSARI BIOTECH LIMITED Q4 & FY26 RESULTS PRESENTATION April 27, 2026
Slide 3: Disclaimer
Disclaimer Certain statements and opinions with respect to the anticipated future performance of Rossari Biotech Ltd (Rossari) in the presentation (“forward-looking statements”) reflect various assumptions concerning the strategies, objectives and anticipated results which may or may not prove to be
Slide 4: Q4 FY26 Results Overview, Company Overview, Annexure
1 Q4 FY26 Results Overview 2 Company Overview 3 Annexure 3
Slide 5: Q4 FY26 – Key Financial Highlights
Q4 FY26 – Key Financial Highlights Strong Quarterly Performance Highest Quarterly Revenue Highest Quarterly EBITDA Highest Quarterly PAT Revenue from Operations (Rs. cr) EBITDA(Rs. cr) PAT(Rs. cr) 684.9 46.0 581.7 579.6 77.3 68.9 69.5 32.8 34.4 Q4 FY26 Q3 FY26 Q4 FY25 Q4 FY26 Q3 FY26 Q4 FY25 Q4 FY26
Slide 6: FY26 – Key Financial Highlights
FY26 – Key Financial Highlights Highest Annual Revenue Highest Annual EBITDA Highest Annual PAT Revenue from Operations (Rs. cr) EBITDA (Rs. cr) PAT (Rs. cr) 149.2 2,396.4 136.4 2,080.3 286.0 265.1 FY26 FY25 FY26 FY25 FY26 FY25 Shift % (Y-o-Y) 15.2% 7.9% 9.4% Margins (%) 11.9% 12.7% 6.2% 6.6% Busine
Slide 7: Institutional and B2C Performance – Incubating Future Growth Verticals in Health & Hygiene
Institutional and B2C Performance – Incubating Future Growth Verticals in Health & Hygiene Revenue (Rs. cr) EBITDA (Rs. cr) FY24 FY25 FY26 299 7 283 179 (3) (15) FY24 FY25 FY26 Shift % (Y-o-Y) 67% -5% - Margins (%) 4% -1% -5% • Performance in the Institutional and B2C segments remained subdued in FY
Slide 8: Consolidated Performance excluding Institutional and B2C Businesses
Consolidated Performance excluding Institutional and B2C Businesses Revenue (Rs. cr) EBITDA (Rs. cr) 301 2,113 268 1,781 243 1,652 FY24 FY25 FY26 FY24 FY25 FY26 Shift % (Y-o-Y) 8% 19% 10% 12% Margins (%) 15% 15% 14% • Core segments delivered strong growth, supported by a diversified portfolio and st
Slide 9: Past Financial Performance Snapshot
Past Financial Performance Snapshot Revenue (Rs. cr) EBITDA (Rs. cr) PAT (Rs. cr) CAGR – 13% CAGR – 9% CAGR – 12% 149 286 131 136 2,396 250 265 2,080 223 107 1,656 1,831 FY23 FY24 FY25 FY26 FY23 FY24 FY25 FY26 FY23 FY24 FY25 FY26 Exports (Rs. cr) ROE (%) ROCE (%) Net Debt to Equity (x) CAGR – 19% 21
Slide 10: Management Message
Management Message Commenting on the performance, in a joint statement, Mr. Edward Menezes, Promoter & Executive Chairman, and Mr. Sunil Chari, Promoter & Managing Director, said “We concluded the year on a strong note, with Q4 FY26 marking our highest-ever quarterly revenue and EBITDA performance.
Slide 11: Key Developments
Key Developments • Unitop commissioned the remaining 15,000 MTPA ethoxylation capacity at its Dahej facility on 31 March 2026, taking total installed ethoxylation capacity to 66,000 MTPA • For FY 2025-26, the Board of Directors recommended a dividend of Re. 0.50 per share • Appointment of Mr. Udeypa
Slide 12: Abridged P&L Statement - Consolidated
Abridged P&L Statement - Consolidated Particulars (Rs. cr) Q4 FY26 Q4 FY25 Y-o-Y FY26 FY25 Y-o-Y Revenues from Operations 684.9 579.6 18.2% 2,396.4 2,080.3 15.2% Total Expenditure COGS 495.7 401.6 23.4% 1,668.7 1,433.3 16.4% Employee benefits expense 39.2 35.5 10.4% 154.7 132.3 16.9% Other expenses
Slide 13: Consolidated Balance Sheet
Consolidated Balance Sheet ASSETS EQUITY AND LIABILITIES Particulars (Rs. cr) As on 31st March As on 31st March As on 31st March As on 31st March Particulars (Rs. cr) 2026 (Audited) 2025 (Audited) 2026 (Audited) 2025 (Audited) ASSETS EQUITY NON-CURRENT ASSETS Equity Share Capital 11.1 11.1 Property,
Slide 14: Consolidated Cash Flow Statement
Consolidated Cash Flow Statement As on 31st As on 31st As on 31st As on 31st Particulars (Rs. cr) March 2026 March 2025 Particulars (Rs. cr) March 2026 March 2025 (Audited) (Audited) (Audited) (Audited) A. Cash flows from operating activities B. Cash flows from investing activities Net redemption fr
Slide 15: Segment-wise Operating Performance
Segment-wise Operating Performance Quarterly Revenue Break-up (Rs. cr) YTD Revenue Break-up (Rs. cr) Q4 FY26 Q3 FY26 Q4 FY25 FY26 FY25 685 2,396 582 580 2,080 530 1,857 441 449 1,620 113 103 94 400 344 42 38 37 139 116 HPPC TSC AHN TOTAL HPPC TSC AHN TOTAL Shift (Y-o-Y) % 18% 20% 14% 18% Shift (Y-o-
Slide 16: Q4 FY26 Results Overview, Company Overview, Annexure
1 Q4 FY26 Results Overview 2 Company Overview 3 Annexure 15
Slide 17: Rossari – At a Glance
Rossari – At a Glance Technocrat promoters with 25% 75+ Revenue CAGR % (FY19-26) cumulative years of experience in the specialty chemicals industry 7* 4* 13% Manufacturing R&D Contribution of Top 10 customers facilities Facilities in FY26 382,100* MTPA 18% Capacity Installed PAT CAGR % (FY19-26) Est
Slide 18: A 25-Year Journey of Transformation
A 25-Year Journey of Transformation Delivering Value and Maintaining Synergy Along the Way Looking back in time Our Company was initially incorporated as ‘Rossari Labtech’ in March, 2003, as a partnership firm. In the same year, in December, the name of the partnership firm was changed to ‘Rossari B
Slide 19: HPPC | Home, Personal Care and Performance Chemicals
Business Overview HPPC | Home, Personal Care and Performance Chemicals One of the Fastest-growing Specialty Chemicals Manufacturers in the HPPC Sector in India Key Metrics as of FY26 77% FY26 Rev. 80 1,750+ 1,050+ 100+ Geographies Customers Products New Products (L3Y) KEY GROWTH DRIVERS Rising Deman
Slide 20: TSC | Textile Specialty Chemicals
Business Overview TSC | Textile Specialty Chemicals One of the Largest Textile Specialty Chemical Manufacturers in India Serving the Full Textile Value Chain From Fibre to Finished Fabric Key Metrics as of FY26 17% FY26 Rev. 29 1,000+ 2,000+ 21+ Geographies Customers Products New Products (L3Y) KEY
Slide 21: AHN | Animal Health Nutrition
Business Overview AHN | Animal Health Nutrition Manufactures a Range of Bio-Based Feed Supplements and Additives, Pet Grooming and Pet Treats by Leveraging Expertise in Life Sciences Key Metrics as of FY26 6% FY26 Rev. 18 125+ 90+ 30+ Geographies Customers Products New Products (L3Y) KEY GROWTH DRIV
Slide 22: Strong Competitive Edge: Reflected in Growth Ahead of the Industry
Strong Competitive Edge Deep relationships with marquee customers and Innovation-driven a growing global differentiation footprint Manufacturing Proven M&A and excellence supported by partnership record with strategic capacity effective integration augmentation Comprehensive product Sustainable valu
Slide 23: Robust Manufacturing Capabilities
Robust Manufacturing Capabilities Unitop Dahej Plant Manufacturing Facility at Dahej 90,000 MTPA • Enjoys proximity to multi-cargo port of Dahej – providing cost & logistical Tristar Sarigam Plant advantage • State-of-the-art facility, well-equipped with advanced technologies 15,000 MTPA • Designed
Slide 24: Growing Global Reach
Growing Global Reach Market Presence RoW India 26% 74% EXPORT OPERATIONS IN 80 COUNTRIES As of FY26
Slide 25: Key Strategic Levers for Growth
Key Strategic Levers for Growth Accelerating growth in core Strengthening 01 business lines 04 international presence • Deepen customer engagement through cross- • Expand international distribution across key sell and solution-led offerings markets • Increase wallet share across domestic and • Broad
Slide 26: Update on Key Subsidiaries
Update on Key Subsidiaries Executed synergistic acquisitions in the past complementing the ethos of Rossari’s business model Description Rationale Revenue (Rs. crore) • Unitop solutions sold across 25+ countries CAGR – 19% • Presence in high-potential Specialty • Expand into surfactants and 922 chem
Slide 27: Key Synergies from Acquisitions
Key Synergies from Acquisitions Strategic & value-accretive acquisitions accelerate growth and drive economies of scale Synergies Realised Value Creation Augmented presence in Specialty • Integrated Chemical, Personal Care and manufacturing led to Agrochemical segments cost saving • Strengthened pre
Slide 28: Focus on Green & Sustainable Chemical Solutions since Inception
Focus on Green & Sustainable Chemical Solutions since Inception Aggressively embracing sustainability in business operations to accelerate growth Operates three Zero Liquid Discharge Specialists in eco-friendly substitutes (ZLD) sites with rainwater harvesting, replacing harmful legacy products, wit
Slide 29: Corporate Social Responsibility
Corporate Social Responsibility We at Rossari, recognize our role and responsibility to deliver sustainable value to communities. Our initiatives are aimed towards upliftment of areas of rural development, women empowerment and livelihood opportunities, research and development for upliftment of soc
Slide 30: Experienced Promoters and Board of Directors
Experienced Promoters and Board of Directors Founders & Promoters Independent Directors • B. Sc. (chemistry major) from K. J. Somaiya College of Science, • Over 25 years of experience in the banking industry. He holds a bachelor’s degree in commerce University of Bombay & B. Sc. (technology) in text
Slide 31: Conference Call Details
CONFERENCE CALL DETAILS Q4 FY-2026 Earnings Conference Call Time 5:00 PM IST on Tuesday, April 28, 2026 Pre-registration To enable participants to connect to the conference call without having to wait for an operator, please register at the below mentioned link: Diamond Pass Registration (choruscall
Slide 32: About Us
About Us Rossari Biotech Limited (Rossari) (BSE: 543213, NSE: ROSSARI), is a Specialty-Chemicals manufacturer providing intelligent and sustainable solutions for customers across industries. Headquartered at Mumbai, India, the Company operates strategically located manufacturing facilities at Silvas
Slide 33: Thank you
Thank y#u ‘making you more compete